A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Inebilizumab (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Nov 2014 Status changed from completed to active, no longer recruiting.
    • 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top